Resources for Patients and their Families

Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma

Brief Summary

The purpose is to evaluate the activity and feasibility of a two drug regimen which is partly orally and partly intravenous in advanced pleural mesothelioma.

Tracking Information
First Received DateJanuary 3, 2006
Last Changed DateSeptember 17, 2009
Start DateSeptember 2004
Actual Primary Completion DateSeptember 2009
Primary Outcome Measures


Secondary Outcome Measures



Descriptive Information
PhasePhase 2
Study TypeInterventional
  • Malignant Pleural Mesothelioma
  • Drug: Carboplatin and Vinorelbine
Detailed Description

Chemotherapy with carboplatin i.v. day one in each cycle Vinorelbine i.v. day one, and orally day 8 in each cycle, repeat new cycle every 3 weeks. Total of 6 cycles.

Endpoint is response rate, secondary endpoints survival and toxicity.

Recruitment Information
Recruitment StatusCompleted
Anticipated Enrollment40
Ages18 Years - 85 Years
Accepts Healthy VolunteersNo
Eligibility Criteria

Inclusion Criteria:

- Histologically verified malignant pleural Mesothelioma

- Age above 18 years

- Performance status 0-2

Exclusion Criteria:

- No previous chemotherapy

- Normal renal, liver and bone marrow function

Administrative Information
SponsorRigshospitalet, Denmark
Verification DateSeptember 2009
Mesothelioma Doctors by State
  • Breaking News
  • Emerging Clinical Trials
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog



Fall 2018 Mesothelioma Cancer Alliance Scholarship Winner Darwin Arias

Prognosis of Mesothelioma Without Treatment

Asbestos Is No Laughing Matter

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: